SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001714899-18-000022
Filing Date
2018-12-06
Accepted
2018-12-06 16:33:36
Documents
6
Period of Report
2018-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q/A form10-qa12518.htm 10-Q/A 96887
2 EXHIBIT 10.2 ex102f-stargammaiplicensea.htm EX-10.2 585302
3 EXHIBIT 10.4 ex104f-starsharepurchaseag.htm EX-10.4 928123
4 EXHIBIT 31.3 ex313form10-qa.htm EX-31.3 6356
5 EXHIBIT 31.4 ex314form10-qa.htm EX-31.4 6318
6 cooleylogo.jpg GRAPHIC 2948
  Complete submission text file 0001714899-18-000022.txt   1628229
Mailing Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-38311 | Film No.: 181221065
SIC: 2836 Biological Products, (No Diagnostic Substances)
Assistant Director 1